[go: up one dir, main page]

GT200100055A - Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas. - Google Patents

Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas.

Info

Publication number
GT200100055A
GT200100055A GT200100055A GT200100055A GT200100055A GT 200100055 A GT200100055 A GT 200100055A GT 200100055 A GT200100055 A GT 200100055A GT 200100055 A GT200100055 A GT 200100055A GT 200100055 A GT200100055 A GT 200100055A
Authority
GT
Guatemala
Prior art keywords
chronic
acute
migraine
neuropathic pain
treatment
Prior art date
Application number
GT200100055A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Brian Thomas O'neill
Steven Bradley Sands
Eric Jacob Watsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100055A publication Critical patent/GT200100055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACEUTICAS PAR EL TRATAMIENTO DEL DOLOR AGUDO, CRONICO Y/O NEUROPATICO. LAS COMOSICIONES FARMACEUTICAS ESTAN COMPRENDIDAS POR UNA COMBINACION TERAPEUTICAMENTE EFICAZ DE UN AGONISTA PARCIAL DE RECEPTORES DE NICOTINA Y UN AGENTE ANAGESICO Y UN VEHICULO FARMACEUTICAMNTE ACEPTABLE. EL AGENTE ANAGESICO SE SELECCIONA DE ANALGEICOS OPIOIDES, ANTAGONISTAS DE NMDA, ANTAGONISTAS DE LA SUSTANCIA P, INHIBIDORES DE COX 1 Y COX 2, ANTIDEPRESIVOS TRICICLICOS (TCA), INHIBIDORES DE LA REABSORCION DE SEROTONINA SELECTIVOS (SSRI), AGONISTAS DE RECEPTORES DE CAPSICINA, AGENTES ANESTESICOS, BENZODIAZEPINAS, RELAJANTES DE LOS MUSCULOS, ESQUELETICOS, AGENTES TERAPEUTICOS PARA LA MIGRAÑA, ANTIHISTAMINICOS, ESTEROIDES, CAFEINA Y TOXINA BOTULINICA. TAMBIEN SE DESCRIBE EL METODO PARA USAR ESTOS COMPUESTOS Y UN METODO PARA TRATAR EL DOLOR AGUDO, CRONICO Y/O NEUROPATICO Y LA MIGRAÑA EN UN MAMIFERO INCLYENDO UN SER HUMANO.
GT200100055A 2000-04-07 2001-04-05 Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas. GT200100055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
GT200100055A true GT200100055A (es) 2001-12-31

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100055A GT200100055A (es) 2000-04-07 2001-04-05 Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas.

Country Status (35)

Country Link
US (2) US20010036943A1 (es)
EP (1) EP1272218B1 (es)
JP (1) JP2003530345A (es)
KR (1) KR20030040201A (es)
CN (1) CN1468111A (es)
AP (1) AP2002002642A0 (es)
AR (1) AR027773A1 (es)
AT (1) ATE291438T1 (es)
AU (1) AU3768001A (es)
BG (1) BG107138A (es)
BR (1) BR0109837A (es)
CA (1) CA2405142A1 (es)
CR (1) CR6767A (es)
CZ (1) CZ20023214A3 (es)
DE (1) DE60109589T2 (es)
EA (1) EA004930B1 (es)
EE (1) EE200200579A (es)
ES (1) ES2236185T3 (es)
GT (1) GT200100055A (es)
HU (1) HUP0301822A3 (es)
IL (1) IL152076A0 (es)
IS (1) IS6560A (es)
MA (1) MA26889A1 (es)
MX (1) MXPA02009817A (es)
NO (1) NO20024734D0 (es)
OA (1) OA12241A (es)
PA (1) PA8515001A1 (es)
PE (1) PE20011307A1 (es)
PL (1) PL365957A1 (es)
SK (1) SK13952002A3 (es)
SV (1) SV2002000377A (es)
TN (1) TNSN01053A1 (es)
WO (1) WO2001076576A2 (es)
YU (1) YU74602A (es)
ZA (1) ZA200207996B (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2002026020A2 (en) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
US8309570B2 (en) * 2001-06-07 2012-11-13 Analgesic Neuropharmaceuticals, Llc Treatment of central neuropathic pain
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
JP2005504058A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患の治療のための置換ヘテロアリール−７−アザ［２．２．１］ビシクロヘプタン
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
WO2003049753A1 (en) * 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
CN1627944A (zh) * 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
WO2003066040A1 (fr) * 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2003070728A2 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
AU2003219690A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
WO2003097038A1 (en) * 2002-05-14 2003-11-27 Ralph Ryback Method for treating dermatoses and tissue damage
JP2006504634A (ja) * 2002-05-15 2006-02-09 アボット・ラボラトリーズ 神経障害性疼痛の治療
MXPA04011416A (es) 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Mejora del desarrollo de las cataratas y otras enfermedades oftalmicas.
JP2006509735A (ja) * 2002-10-17 2006-03-23 ノバルティス アクチエンゲゼルシャフト オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド（−Ｉ）
EP1578787B1 (en) 2002-12-02 2012-11-14 Xenome Ltd Novel chi-conotoxin peptides (-ii)
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
WO2004078201A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004092122A2 (en) * 2003-04-08 2004-10-28 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7268109B2 (en) * 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
JP2007511520A (ja) 2003-11-13 2007-05-10 ザ ジェネラル ホスピタル コーポレーション 疼痛を治療するための方法
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006047279A2 (en) * 2004-10-21 2006-05-04 University Of Iowa Research Foundation In situ controlled release drug delivery system
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2008010223A2 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
WO2008020651A1 (fr) * 2006-08-17 2008-02-21 Kyushu University, National University Corporation antagoniste de récepteur P2X4
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20080119820A1 (en) 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
MX2010002692A (es) 2007-09-13 2010-06-01 Concert Pharmaceuticals Inc Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
US20100312073A1 (en) * 2008-01-31 2010-12-09 David Yarnitsky Method of predicting pain medication efficacy
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
PT2582366E (pt) 2010-06-15 2016-01-26 Gruenenthal Gmbh Combinação terapêutica para o tratamento da dor
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CN103764136A (zh) * 2011-02-18 2014-04-30 雀巢产品技术援助有限公司 用于治疗、减轻或预防动物神经系统损害的方法和组合物
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
KR20150042269A (ko) * 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피라졸
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
WO2018175696A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
WO2018191480A1 (en) * 2017-04-12 2018-10-18 Synergistic Therapeutics. Llc Therapeutic neuropathic pain lotion
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621707B2 (ja) * 1996-10-30 2005-02-16 ファイザー・インク ピリドン―縮合したアザ二環式―またはシチシン誘導体、その製法および嗜癖治療におけるその用途
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
KR100420423B1 (ko) * 1998-04-29 2004-03-04 화이자 프로덕츠 인코포레이티드 아릴 축합된 아자 다환식 화합물
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
WO2001076576A2 (en) 2001-10-18
DE60109589T2 (de) 2005-09-01
EA200200910A1 (ru) 2003-02-27
IL152076A0 (en) 2003-05-29
PL365957A1 (en) 2005-01-24
YU74602A (sh) 2006-05-25
IS6560A (is) 2002-09-20
CA2405142A1 (en) 2001-10-18
WO2001076576A3 (en) 2002-06-20
EE200200579A (et) 2004-06-15
EP1272218A2 (en) 2003-01-08
ATE291438T1 (de) 2005-04-15
CR6767A (es) 2004-06-09
DE60109589D1 (de) 2005-04-28
PA8515001A1 (es) 2002-02-21
JP2003530345A (ja) 2003-10-14
ZA200207996B (en) 2003-10-20
AU3768001A (en) 2001-10-23
HUP0301822A3 (en) 2005-06-28
MA26889A1 (fr) 2004-12-20
NO20024734D0 (no) 2002-10-02
AP2002002642A0 (en) 2002-12-31
TNSN01053A1 (fr) 2005-11-10
KR20030040201A (ko) 2003-05-22
EA004930B1 (ru) 2004-10-28
SK13952002A3 (sk) 2003-12-02
CZ20023214A3 (cs) 2003-11-12
CN1468111A (zh) 2004-01-14
US20030133951A1 (en) 2003-07-17
BR0109837A (pt) 2003-01-21
MXPA02009817A (es) 2003-03-27
BG107138A (en) 2003-05-30
OA12241A (en) 2004-01-27
EP1272218B1 (en) 2005-03-23
US20010036943A1 (en) 2001-11-01
SV2002000377A (es) 2002-07-03
HUP0301822A2 (hu) 2003-11-28
ES2236185T3 (es) 2005-07-16
AR027773A1 (es) 2003-04-09
PE20011307A1 (es) 2001-12-28

Similar Documents

Publication Publication Date Title
GT200100055A (es) Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas.
Segraws Antidepressant-induced orgasm disorder
RU99117926A (ru) Лекарственные формы и способ лечения расстройства мужской эректильной функции
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
AR013240A1 (es) Composiciones, equipos y metodos para inhibir los deseordenes neurovasculares cerebrales y los dolores de cabeza musculares
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CO5540290A2 (es) Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
Makhija et al. Reconsidering pimozide for new-onset delusions of parasitosis
Malmberg et al. Antinociceptive effect of α-trinositol, a novel d-myo-inositol phosphate derivative, in the formalin test in rats
CO5700713A2 (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion a nicotina en un mamifero
ATE288756T1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
Iorio et al. Interaction studies in mice of SCH 29851, a potential nonsedating antihistamine, with commonly used therapeutic agents